Trial Profile
Phase II study of NRX 195183 therapy for patients with relapsed or refractory acute promyelocytic leukemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs IRX 5183 (Primary)
- Indications Acute promyelocytic leukaemia
- Focus Therapeutic Use
- Sponsors NuRx Pharmaceuticals
- 03 Jun 2008 New trial record.